Because it helps get the right drug to the right patient at the right time. It’s how we really move to ‘value-based care’ or ‘outcome driven healthcare.’ It can help open new doors beyond the ‘standard of care’ which is more of a one-size-fits-all approach to cancer care that doesn’t take into consideration the uniqueness of you.
Cancer is a genetic disease. The DNA of your cells have become mutated. You need to know the mutations in your tumor. This will help you and your doctor select treatment options, including clinical trials, that are likely to work best for you and may not be considered otherwise. A treatment that works well for one person may not work as well for you.
All advanced cancer patients deserve to have new doors opened. We all want new hope. Besides the standard of care, we have the right to consider targeted therapy (i.e. drugs specifically built to go after the mutations driving your disease), appropriate clinical trials that go after the same molecular targets driving your cancer, or off label treatments that may be effective for your specific tumor mutations. There are also genomic signatures like TMB (tumor mutational burden) and MSI (microsatellite instability) and PD-L1 expression that are biomarkers that are very helpful in determining whether you’d be a good fit for new immunotherapy treatments or not. Don’t you want to know?